Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Norikazu MasudaHirofumi MukaiKenichi InoueYoshiaki RaiShinji OhnoShoichiro OhtaniChikako ShimizuSatoshi HashigakiYasuaki MuramatsuYoshiko UmeyamaHiroji IwataMasakazu ToiPublished in: Breast cancer (Tokyo, Japan) (2020)
The types of first subsequent therapy received by Japanese patients in the palbociclib plus ET and placebo plus ET groups were similar. Further evaluation of subsequent therapy data in the real-world setting is warranted considering the small sample size of this analysis.